KPIs & Operating Metrics(New)
Growth Metrics

Johnson & Johnson (JNJ) Long-Term Investments (2009)

Johnson & Johnson recorded quarterly Long-Term Investments of $19.0 million in Q3 2009, up 5.56% quarter-over-quarter from $18.0 million in Q2 2009.

Johnson & Johnson's Long-Term Investments history runs 1 years deep, the most recent figure standing at $19.0 million for Q3 2009.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - 100.00 Mn
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 3.12 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 268.00 Mn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 1.11 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 983.00 Mn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 1.63 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 366.00 Mn
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Sep 27, 2009 19.00 Mn
Jun 28, 2009 18.00 Mn